A. Overall 95% sustained virologic response (SVR) at 12 weeks B. Overall 90% SVR at week 24 in patients not receiving hemodialysis C. Eighty-eight percent to 92% SVR in patients with genotypes 1, 2, or 6 D. Ninety-seven percent SVR at week 12, falling to 90% SVR at week 24

A. Every week for the first 4 weeks; thereafter, every 4 weeks for medication refill and measurement of HIV viral load, HCV viral load, and kidney and liver function. B. Every 4 weeks for medication refill, measurement of HCV viral load, and kidney/liver function – the same as for mono-infected HCV patients. C. Every 8 weeks for medication refill and kidney/liver function tests followed by HCV viral load at week 24. D. Every 12 weeks to measure HCV viral load to determine if another round of DAA therapy is warranted

A. Patients must have a representative from either their doctor's office or pharmacy submit an application on their behalf to financial assistance foundations. B. Patients may have a maximum dollar amount from the financial assistance foundation for which he/she is eligible depending on the state in which they reside. C. Patients can apply for co-payment assistance or may request a drug at no cost from the drug manufacturer through patient assistance programs. D. Co-payment assistance funds through the manufacturer are not capped, but the patient must be on Medicaid

A. HIV/HCV-coinfected persons should be treated and retreated the same as persons without HIV infection after recognizing and managing interactions with antiretroviral medications. B. Daily daclatasvir plus sofosbuvir (400 mg), with or without ribavirin, is a recommended treatment regimen when antiretroviral regimen changes cannot be made to accommodate alternative HCV direct-acting antivirals. C. Antiretroviral treatment interruption to allow HCV therapy is not recommended. D. Treatment courses shorter than 12 weeks are encouraged when low HCV viral loads are achieved by week 4 in combination with maintenance of low HIV viral loads.

A. He is not a good candidate for HCV treatment because of how long he has been infected with HIV. B. Pill burden will not be a problem because the dosage of HCV direct-acting agents (DAAs) will be reduced to avoid drug-drug interactions. C. His pill burden may be high but the treatment duration for HCV is short, and there are several options for financial assistance for HCV DAA therapy. D. Neither pill burden nor cost will be an issue because of the newer combination therapies that include both HAART for HIV, plus DAAs for HCV, which are covered by Medicaid